丁苯酞联合阿替普酶治疗对急性缺血性脑卒中患者神经功能凝血功能血清TNF-α hs-CRP Hcy水平的影响

doi:10.3969/j.issn.1006-6233.2021.01.035

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1304 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨丁苯酞联合阿替普酶治疗对急性缺血性脑卒中患者疗效和安全性及对卒中患者神经功能、凝血功能、超敏c反应蛋白(hs-CRP)、血清肿瘤坏死因子-α(TNF-α)、同型半胱氨酸(Hcy)水平的影响。方法: 收集134例急性缺血性脑卒中患者,随机数字表法分为两组,对照组67例,采用基础治疗+阿替普酶,联合组采用基础治疗+阿替普酶+丁苯酞,治疗2周后,对比两组临床疗效,评估、检测并比较两组美国国立卫生研究院卒中量表(NIHSS)评分、脑梗死体积、血神经元特异烯醇化酶(NSE)、S100β蛋白(S100β)、纤维蛋白原(FIB)、D-二聚体(D-D)、凝血酶原时间(PT)、部分活化凝血酶活化时间(APTT)、TNF-α、hs-CRP、Hcy。结果: 联合组治疗效果优于对照组,差异有统计学意义(P<0.05)。两组治疗后NIHSS评分、脑梗死体积、NSE、S100β均与本组治疗前相比降低,且联合组治疗后低于对照组治疗后,差异均有统计学意义(P<0.05);治疗后两组FIB、D-D均与本组治疗前比较降低,APTT、PT升高;且联合组治疗后FIB、D-D均低于对照组治疗后,APTT、PT均高于对照组治疗后,差异均有统计学意义(P<0.05)。两组治疗后TNF-α、hs-CRP、Hcy均与本组治疗前比较降低,且联合组治疗后TNF-α、hs-CRP、Hcy均低于对照组治疗后,差异均有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论: 与单纯阿替普酶治疗相比,联合丁苯酞可以提高急性缺血性脑卒中患者治疗效果,促进神经功能恢复,改善凝血功能,降低炎症反应,且安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘海超
	闫建炜
	温宏峰
	王培福

关键词 ：丁苯酞, 阿替普酶, 急性缺血性脑卒中, 神经功能, 凝血功能, 炎症

Abstract：Objective: To observe the clinical effect and safety of Ateplase combined with Agatroban on acute ischemic stroke (AIS) and its influence on neurological function and coagulation function and serological indexes such as high sensitive C reaction protein (hs-CRP)、tumornecrosis factor-α (TNF-α) and homocysteine (Hcy). Methods: A total of 134 patients with AIS were selected and divided into two groups by random number table method. The control group consisted of 67 patients who received basic treatment + alteplase and the combination group received basic treatment + alteplase + butylphthal. Both groups were treated for 2 weeks, and the clinical efficacy was compared. National Institutes of Health Stroke Scale (NIHSS), cerebral infarction volume, neuron-specific enolase (NSE), S100β protein, fibrinogen (FIB), D-dimer (D-D), prothrombin time (PT) , activated partial thromboplastin time (APTT), TNF-α, hs-CRP and Hcy was evaluated, detected, and compared. Results: The efficacy of the combination group was better than control group, respectively,with significant difference (P<0.05). Comparison before treatment revealed that the NIHSS score, cerebral infarction volume, NSE, S100β, FIB and D-D in the two groups were lower, and APTT and PT were increased after treatment. Compared with the control group, and NIHSS score, cerebral infarction volume, NSE, S100β, FIB and D-D in combination group was lower, while APTT and PT were increased after treatment, suggesting significant difference (P<0.05). After treatment, the TNF-α, hs-CRP, and Hcy in both groups were lower than those before treatment, and the TNF-α, hs-CRP, and Hcy in the combination group were lower than the control group, with statistical significance (P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Butylphthal combined with alteplase can improve the treatment effect, promote nerve function recovery, improve coagulation function, reduce the inflammatory reaction, and has good safety of patients with AIS, compared to the alteplase alone treatment.

Key words： Butyphthal Alteplase Acute ischemic stroke Neurological function Coagulation function inflammation

基金资助:北京市科技计划课题,(编号:Z171100001017137)

引用本文:

刘海超, 闫建炜, 温宏峰, 王培福. 丁苯酞联合阿替普酶治疗对急性缺血性脑卒中患者神经功能凝血功能血清TNF-α hs-CRP Hcy水平的影响[J]. 河北医学, 2021, 27(1): 150-155.
LIU Haichao, YAN Jianwei, EN Hongfeng, et al. Effect of Butyphthal Combined with Alteplase on Neurological Function and Coagulation Function and Serological Indexes as TNF-α hs-CRP and Hcy in Patients with Acute Ischemic Stroke. HeBei Med, 2021, 27(1): 150-155.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.01.035 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I1/150

[1] Song TJ,Kim J,Song D, et al. Total cerebral small-vessel disease score is associated with mortality during follow-up after acute ischemic stroke[J].Clin Neurol, 2017, 13(2):187~195.
[2] 赵岩,吕涌涛.尿激酶对脑组织影响的研究进展[J].中国医药导报,2017,14(11):43~46.
[3] 朱烨,吴雅利,李宝香,等.丁苯酞联合阿替普酶对急性脑梗死患者神经功能、认知功能和Hcy等血清学指标的影响[J].中国药房,2018,29(8):1095~1098.
[4] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666~682.
[5] 谷聚贤,安泽鑫,王妍,等.阿替普酶联合阿加曲班治疗急性缺血性脑卒中的效果观察及对神经功能、炎性因子的影响[J].临床误诊误治,2019,32(12):44~49.
[6] 陈海云,何超明.丁苯酞联合依达拉奉治疗通过降低颈动脉内膜中膜厚度改善老年急性脑梗死患者神经功能[J].中国动脉硬化杂志,2019,27(1):74~77.
[7] Purrucker J C, Rizos T, Haas K, et al. Coagulation testing in intracerebral hemorrhage related to non-vitamin K antagonist oral anticoagulants[J]. Neurocrit Care, 2017,27(2):208~213.
[8] Acibuca A, Vurgun VK, Gerede DM, et al. Serum neuron-specific enolase, a marker of neuronal injury, increases after catheter ablation of atrial fibrillation[J].Int Med Res, 2018, 46(11):4518~4526.
[9] 王洪志,张静波,于远军.丁苯酞联合阿替普酶治疗对急性缺血性脑卒中患者血清NSE、S100β水平的影响[J].卒中与神经疾病,2017,24(6):530~533.
[10] 褚洪高,唐倩,赵洋.阿替普酶联合丁苯酞对急性脑梗死患者神经功能及血清应激因子的影响[J].解放军医药杂志,2017,29(6):103~106.
[11] Shi Z, Liu S, Guan Y, et al. Changes in total homocysteine levels after acute stroke and recurrence of stroke[J]. Sci Rep, 2018, 8(1):6993~6998.
[12] Zhao Y, Lee JH, Chen D, et al. DL-3-n-butylphthalide induced neuroprotection, regenerative repair, functional recovery and psychological benefits following traumatic brain injury in mice[J]. Neurochem Int, 2017, 111 (1):82~92.